Clinical trials: Anaplastic Astrocytomas
High Grade Glioma, Astrocytoma, Grade III
Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
This is a Phase 2 study of newly diagnosed patients with high grade glioma (HGG) undergoing standard radiation therapy and temozolomide treatment.
- Conditions
- High Grade Glioma, Astrocytoma, Grade III, Glioblastoma
- Trial name
- BMX-HGG (NCT02655601)
- Testing
- BMX-001, Radiation Therapy, Temozolomide
- Where
- 9 sites in United States
- Volunteers
- 177 people
- Sponsor
- BioMimetix JV, LLC
Adult Anaplastic Astrocytoma, Recurrent Grade III Glioma
A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas
RATIONALE: Genetically-modified neural stem cells (NSCs) that convert 5-fluorocytosine (5-FC) into the chemotherapy agent 5-FU (fluorouracil) at sites of tumor in the brain may be an effective treatment for glioma.
- Conditions
- Adult Anaplastic Astrocytoma, Recurrent Grade III Glioma, Recurrent Grade IV Glioma, Adult Anaplastic Oligodendroglioma
- Trial name
- NCT01172964
- Testing
- flucytosine, polymerase chain reaction, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Astrocytoma, Grade III, Glioblastoma
Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.
This is a three parallel cohort, open-labeled, non-randomized, multicenter study. All three cohorts will enroll independently.
- Trial name
- STEAM (NCT03224104)
- Testing
- TG02, Radiation Therapy, Temozolomide
- Where
- 10 sites in Austria, France and 3 more
- Volunteers
- 71 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Oligodendroglioma; Oligoastrocytoma
Primary Chemotherapy by BCNU-TMZ Combination in Newly Diagnosed Anaplastic Oligodendrocytic Tumors: Phase II Trial With Translational Molecular Analysis
The first-line treatment of anaplastic oligodendrogliomas, radiotherapy exclusive or combined with PCV, will be defined by the pending results of phase III of the EORTC.
- Trial name
- TEMOBIC (NCT04755023)
- Testing
- Bis-Chloroethyl-Nitroso-Urea (BCNU) withTemozolomide
- Where
- France
- Volunteers
- 53 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Glioblastoma Multiforme, Astrocytoma, Grade III
Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine
The purpose of this study is to determine whether Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine is an feasible and safe treatment for pediatric patients with newly-diagnosed High-Grade Gliomas or recurrent, resectable…
- Conditions
- Glioblastoma Multiforme, Astrocytoma, Grade III, Anaplastic Ependymoma, Clear Cell Ependymoma
- Trial name
- NCT02722512
- Testing
- Heat Shock Protein Peptide Complex-96 (HSPPC-96), Tumor Resection, Radiation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Brain and Central Nervous System Tumors
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Erlotinib and sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of erlotinib when given…
- Trial name
- NCT00509431
- Testing
- Erlotinib + Sirolimus
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain and Central Nervous System Tumors
SarCNU in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of sarCNU in treating patients who have recurrent…
- Trial name
- NCT00036660
- Testing
- SarCNU
- Where
- 5 sites in Canada
- Volunteers
- 10 people
- Sponsor
- NCIC Clinical Trials Group
Malignant Glioma, Recurrent Ependymoma
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
This study will evaluate the administration of AdV-tk followed by valacyclovir in children with malignant glioma, including glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), as well as recurrent ependymomas in…
- Trial name
- NCT00634231
- Testing
- AdV-tk, valacyclovir, Radiation
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Candel Therapeutics, Inc.
Supratentorial Neoplasms, Malignant, Malignant Glioma
HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors
This study is a clinical trial to determine the safety of injecting G207 (a new experimental virus therapy) into a recurrent or progressive brain tumor.
- Conditions
- Supratentorial Neoplasms, Malignant, Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma
- Trial name
- NCT02457845
- Testing
- G207
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Gregory K. Friedman, MD
Malignant Glioma, Glioblastoma Multiforme
Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma
The purpose of this study was to evaluate the safety and potential efficacy of CAN-2409 (also known / previously described as AdV-tk, GMCI) for malignant gliomas.
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High Grade Glioma
- Trial name
- BrTK02 (NCT00589875)
- Testing
- CAN-2409, Valacyclovir, Temozolomide
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Candel Therapeutics, Inc.
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Brain Tumors
Dose Response of Functionally Critical Brain Regions for Brain Radiotherapy
Normal tissue response is critical for brain radiotherapy, especially for dose escalation which carries with it an increased incidence of radiation-induced brain injury.
- Trial name
- NCT01212237
- Testing
- fMRI Evaluation
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Recurrent High-grade Glioma, Recurrent Glioblastoma
Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas
This is a multi-centered, radiation dose escalation, open, exploratory, Phase 1/2a clinical trial on the safety, efficacy and pharmacokinetic characteristics of BNCT in patients with recurrent high-grade gliomas.
- Conditions
- Recurrent High-grade Glioma, Recurrent Glioblastoma, Recurrent Anaplastic Astrocytoma, Recurrent Anaplastic Oligodendroglioma
- Trial name
- NCT05737212
- Testing
- 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 9Gy-Eq, 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 11Gy-Eq, 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 13Gy-Eq
- Where
- South Korea
- Volunteers
- 7 people
- Sponsor
- Dawonmedax Co., Ltd.
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III
A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of zedoresertib combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and…
- Trial name
- NCT05765812
- Testing
- Zedoresertib, Temozolomide, Radiotherapy
- Where
- 16 sites in United States, Spain and 1 more
- Volunteers
- 116 people
- Sponsor
- Debiopharm International SA
Glioblastoma Multiforme, Astrocytoma Anaplastic Foci
Access Protocol for MAB-425 Radiolabeled With I-125 for High Grade Gliomas
The purpose of this access protocol is to allow patients with brain tumors who had previously received 125I-MAB 425 to receive additional course(s) of 125I-MAB 425 until their brain tumor begins to grow, they develop side effects…
- Trial name
- NCT01317888
- Testing
- MAB-425 radiolabeled with I-125
- Volunteers
- 11 people
- Sponsor
- Drexel University
Glioblastoma, Glioblastoma Multiforme
Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme
One of Disulfiram antitumor effects suggested in preclinical studies is MGMT (methyl-guanine-methyl-transferase) inhibition. Disulfiram MGMT inhibitory effect is enhanced by addition of Copper.
- Trial name
- NCT03363659
- Testing
- Disulfiram, Copper gluconate, Temozolomide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Wake Forest University Health Sciences
Brain and Central Nervous System Tumors, Thromboembolism
Risk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed Gliomas
RATIONALE: Patients with gliomas may be at risk for developing blood clots. Learning about the risk factors for developing blood clots may help doctors plan better treatment for gliomas.
- Trial name
- NCT00253669
- Testing
- laboratory biomarker analysis, physiologic testing, management of therapy complications
- Where
- 9 sites in United States
- Volunteers
- 110 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma, Gliosarcoma
Sorafenib in Newly Diagnosed High Grade Glioma
This is a phase I study to evaluate the safety and tolerability of Sorafenib in combination with Temodar and radiation therapy in patients with newly diagnosed high grade glioma (glioblastoma, gliosarcoma, anaplastic astrocytoma…
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
- Trial name
- NCT00884416
- Testing
- Sorafenib dose escalation
- Where
- Switzerland
- Volunteers
- 17 people
- Sponsor
- University Hospital, Geneva
Brain and Central Nervous System Tumors
Cytotoxic T Cells and Interleukin-2 in Treating Adult Patients With Recurrent Brain Tumors
RATIONALE: Biological therapy uses different ways to stimulate the immune system and stop cancer cells from growing. Cytotoxic T cells combined with interleukin-2 may be an effective treatment for recurrent brain tumors.
- Trial name
- NCT00002572
- Testing
- aldesleukin, muromonab-CD3, therapeutic tumor infiltrating lymphocytes
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver
Glioblastoma, Gliosarcoma
Ph II Bevacizumab + Etoposide for Pts w Recurrent MG
Primary Objective to estimate 6-month progression free survival probability of patients with recurrent malignant glioma treated with Etoposide + Bevacizumab.
- Trial name
- NCT00612430
- Testing
- Bevacizumab and Etoposide
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Duke University